Consumer Recall Of OTC Advertising "Much Higher" Than DTC Ads In Study
This article was originally published in The Tan Sheet
Executive Summary
OTC advertising was found to generate "much higher awareness levels than their direct-to-consumer counterparts," Campbell Mithun Esty Health concludes in a two-part study conducted in November 1998 and last June. "Yet ad spending levels between the two groups were comparable," the firm notes, adding OTC brands spend an average $39.4 mil. in media, and DTC brands $43.6 mil.
You may also be interested in...
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)